* Abeona Therapeutics Inc ABEO.OQ ABEO.O is expected
to show a
fall in quarterly revenue when it reports results on August 9
(estimated).
*
* Refinitiv's mean analyst estimate for Abeona Therapeutics
Inc
is for a loss of 68 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Abeona
Therapeutics Inc is $19, above its last closing price
of $3.14.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.62 -0.58 -0.54 Beat 6.9
Dec. 31 2023 -0.75 1.53 Beat 304
Sep. 30 2022 -1.75 -1.75 -1.48 Beat 15.3
Jun. 30 2022 -1.94 -1.87 -2.08 Missed -10.9
Mar. -2.00 -2.37 -3.50 Missed -47.4
31 2022
Dec. 31 2021 -4.67 -3.67 -3.50 Beat 4.5
Sep. 30 2021 -4.09 -4.06 -4.00 Beat 1.5
Jun. 30 2021 -4.12 -4.12 -4.00 Beat 3
This summary was machine generated August 7 at 18:32 GMT. All
figures in US dollars unless otherwise stated